Clinical trial
Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease
NCT00003936 · Barbara Ann Karmanos Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00003936 |
|---|---|
| Title | Bryostatin 1 in Treating Patients With Recurrent or Refractory Hodgkin's Disease |
| Official title | Phase II Clinical Evaluation of Bryostatin 1 in Patients With Hodgkin's Disease |
| Lead sponsor | Barbara Ann Karmanos Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | bryostatin 1 |
| Start date | Jun 1, 1999 |
| Primary completion | Jun 1, 2004 |
| Completion | Jun 1, 2004 |
| First posted | Jul 26, 2004 |
| Last update posted | Apr 11, 2014 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: